

Anti-PAI-1 (human, plasminogen activator inhibitor type I)
Mouse monoclonal antibody

Subclass: IgG1

PRODUCT NO.	MON I-5
PRESENTATION	Preparation: Protein-G purified Content: Available in 200 µL and 1 mL volumes, 1 mg/mL Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide Storage: In the dark at 4-8°C
ANTIGEN	Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). It belongs to the group of serpins (serine protease inhibitors). Elevated levels of PAI-1 are associated with poor prognosis in many types of cancer (1-5).
IMMUNOGEN	Native PAI-1
SPECIFICITY	MON I-5 is specific for human PAI-1. No cross-reactivity is observed with PAI-2 as tested by ELISA and immunoblotting. No reactivity is observed with any other human plasma protein when tested by immunoblotting.
EPI TOPE SPECIFICITY	MON I-5 binds to an epitope consisting of amino acids 284-294 (6)
REACTIVITY	MON I-5 reacts with PAI-1 as tested by ELISA and immunoblotting and can be used as coating antibody for uPA:PAI-1 ELISA (7). For immunohistochemistry applications MON I-5 can be used on frozen sections.

CULTURE MEDIUM RPMI 1640 with 10% fetal calf serum

FUSION PARTNER NCI-Ag 4/1

IMMUNIZATION Female BALB/c mice immunized by intradermal injection

APPLICATION	Method	Usability	Dilution guideline	References
	ELISA	Yes		7
	Immunoblotting	Yes		
	Immunohistochemistry	Yes		

REFERENCES	<ol style="list-style-type: none"> Andreasen PA (2007) PAI-1 - a potential therapeutic target in cancer. <i>Current Drug Target</i> 9:1030-1041 Loskutoff DJ, Curriden SA, Hu G, Deng G (1999) Regulation of adhesion by PAI-1. <i>APMIS</i> 107:54-61. Andreasen PA, Kjøller L, Christensen (1997) The urokinase plasminogen activator system in cancer metastasis. A review. <i>Int J Cancer</i> 2:1-22. Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase -type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). <i>Cancer Res</i> 62:4617-22. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. <i>Cancer Res</i> 53:2513-2521. Munch M, Heegaard C, Jensen PH, Andreasen PA (1991) Type-1 inhibitor of plasminogen activators. Distincton between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. <i>FEBS Lett</i> 295: 102-106. Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW (1997) The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. <i>J Imm Meth</i> 203:55-65.
------------	---

CONDITIONS

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.